Title : In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation.

Pub. Date : 2021 Mar

PMID : 32102624






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. osimertinib epidermal growth factor receptor Homo sapiens
2 Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. osimertinib epidermal growth factor receptor Homo sapiens
3 However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs. osimertinib epidermal growth factor receptor Homo sapiens